Unknown

Dataset Information

0

Perioperative fosfomycin disodium prophylaxis against urinary tract infection in renal transplant recipients: a randomized clinical trial.


ABSTRACT: BACKGROUND:Symptomatic urinary tract infection (UTI) is the most common infectious complication in renal transplant recipients (RTRs). Fosfomycin (FOS) is an attractive alternative for prophylaxis because it does not interact with immunosuppressants; although 90% is excreted unchanged in the urine, it does not require adjustment for renal function for single dose prophylaxis. METHODS:RTRs were recruited into this randomized, double-blind, placebo-controlled trial. Participants were randomized (1:1) to receive one 4?g dose of FOS disodium intravenously 3?h (FOS group) or placebo (placebo group) before placement and removal of a urinary catheter and before removal of a double-J ureteral stent. All participants received prophylaxis with trimethoprim/sulfamethoxazole. The main outcome was a comparison of the mean number of symptomatic UTI and asymptomatic bacteriuria (AB) episodes per patient during a 7-week follow-up period. The study was registered at ClinicalTrials.gov, NTC03235947. RESULTS:Eighty-two participants were included (41 in the FOS group and 41 in placebo group). The mean number of AB or symptomatic UTI episodes per patient was lower in the FOS group [intention-to-treat (ITT) 0.29 versus 0.60, P?=?0.04]. The incidence of symptomatic UTI was lower in the FOS group (ITT, 7.3% versus 36.6%, P?=?0.001), and there was no difference in the incidence of AB between both groups. The incidence of adverse events was similar in both groups. CONCLUSIONS:FOS addition is an effective and safe strategy to reduce the number of symptomatic UTIs during the first 7?weeks after renal transplant.

SUBMITTER: Rosado-Canto R 

PROVIDER: S-EPMC7643671 | biostudies-literature | 2020 Nov

REPOSITORIES: biostudies-literature

altmetric image

Publications

Perioperative fosfomycin disodium prophylaxis against urinary tract infection in renal transplant recipients: a randomized clinical trial.

Rosado-Canto Rodrigo R   Parra-Avila Idalia I   Tejeda-Maldonado Javier J   Kauffman-Ortega Cristopher C   Rodriguez-Covarrubias Francisco T FT   Trujeque-Matos Mariedel M   Cruz-Martínez Rodrigo R   Maravilla-Franco Ernesto E   Criollo-Mora Elia E   Arreola-Guerra José M JM   Morales-Buenrostro Luis E LE   Sifuentes-Osornio José J  

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20201101 11


<h4>Background</h4>Symptomatic urinary tract infection (UTI) is the most common infectious complication in renal transplant recipients (RTRs). Fosfomycin (FOS) is an attractive alternative for prophylaxis because it does not interact with immunosuppressants; although 90% is excreted unchanged in the urine, it does not require adjustment for renal function for single dose prophylaxis.<h4>Methods</h4>RTRs were recruited into this randomized, double-blind, placebo-controlled trial. Participants wer  ...[more]

Similar Datasets

| S-EPMC4675517 | biostudies-other
| S-EPMC6680096 | biostudies-literature
| S-EPMC6668100 | biostudies-literature
| S-EPMC9237017 | biostudies-literature
| S-EPMC9207318 | biostudies-literature
| S-EPMC7216873 | biostudies-literature
| S-EPMC6555162 | biostudies-literature
| S-EPMC6770760 | biostudies-literature
| S-EPMC6310478 | biostudies-literature
| S-EPMC4886901 | biostudies-literature